Trials / Completed
CompletedNCT03303105
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly \[except for a loading dose of 675 mg for CM patients\] or at 675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TEV-48125 | TEV-48125 will be administered subcutaneously once every 4 weeks. |
| DRUG | TEV-48125 | TEV-48125 will be administered subcutaneously once every 12 weeks. |
Timeline
- Start date
- 2017-12-07
- Primary completion
- 2020-06-16
- Completion
- 2020-06-16
- First posted
- 2017-10-05
- Last updated
- 2023-02-17
- Results posted
- 2021-07-16
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03303105. Inclusion in this directory is not an endorsement.